358 related articles for article (PubMed ID: 21067312)
1. Tumor vaccines and beyond.
Melenhorst JJ; Barrett AJ
Cytotherapy; 2011 Jan; 13(1):8-18. PubMed ID: 21067312
[TBL] [Abstract][Full Text] [Related]
2. Minor histocompatibility antigens: allo target molecules for tumor-specific immunotherapy.
Goulmy E
Cancer J; 2004; 10(1):1-7. PubMed ID: 15000488
[TBL] [Abstract][Full Text] [Related]
3. Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives.
Chen X; Yang J; Wang L; Liu B
Theranostics; 2020; 10(13):6011-6023. PubMed ID: 32483434
[TBL] [Abstract][Full Text] [Related]
4. Specificity in cancer immunotherapy.
Schietinger A; Philip M; Schreiber H
Semin Immunol; 2008 Oct; 20(5):276-85. PubMed ID: 18684640
[TBL] [Abstract][Full Text] [Related]
5. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
Front Immunol; 2018; 9():947. PubMed ID: 29770138
[TBL] [Abstract][Full Text] [Related]
6. The identification of cancer antigens: impact on the development of cancer vaccines.
Rosenberg SA
Cancer J; 2000 Apr; 6 Suppl 2():S142-9. PubMed ID: 10803829
[No Abstract] [Full Text] [Related]
7. Harnessing neoantigen specific CD4 T cells for cancer immunotherapy.
Brightman SE; Naradikian MS; Miller AM; Schoenberger SP
J Leukoc Biol; 2020 Apr; 107(4):625-633. PubMed ID: 32170883
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of cancer through targeting of minor histocompatibility antigens.
Hambach L; Goulmy E
Curr Opin Immunol; 2005 Apr; 17(2):202-10. PubMed ID: 15766682
[TBL] [Abstract][Full Text] [Related]
9. Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy.
Seremet T; Brasseur F; Coulie PG
Cancer J; 2011; 17(5):325-30. PubMed ID: 21952282
[TBL] [Abstract][Full Text] [Related]
10. CD4 T cells and their role in antitumor immune responses.
Toes RE; Ossendorp F; Offringa R; Melief CJ
J Exp Med; 1999 Mar; 189(5):753-6. PubMed ID: 10049938
[No Abstract] [Full Text] [Related]
11. Cancer vaccines: progress reveals new complexities.
Yu Z; Restifo NP
J Clin Invest; 2002 Aug; 110(3):289-94. PubMed ID: 12163445
[No Abstract] [Full Text] [Related]
12. Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses.
Kumai T; Lee S; Cho HI; Sultan H; Kobayashi H; Harabuchi Y; Celis E
Cancer Immunol Res; 2017 Jan; 5(1):72-83. PubMed ID: 27941004
[TBL] [Abstract][Full Text] [Related]
13. MHC class I TCR engineered anti-tumor CD4 T cells: implications for cancer immunotherapy.
Chhabra A
Endocr Metab Immune Disord Drug Targets; 2009 Dec; 9(4):344-52. PubMed ID: 19807670
[TBL] [Abstract][Full Text] [Related]
14. MHC class II restricted tumor antigens and the role of CD4+ T cells in cancer immunotherapy.
Topalian SL
Curr Opin Immunol; 1994 Oct; 6(5):741-5. PubMed ID: 7826529
[TBL] [Abstract][Full Text] [Related]
15. Tumour escape from the immune response: the last hurdle for successful immunotherapy of cancer?
Pawelec G
Cancer Immunol Immunother; 1999 Oct; 48(7):343-5. PubMed ID: 10501845
[No Abstract] [Full Text] [Related]
16. T cells work together to fight cancer.
Cerundolo V
Curr Biol; 1999 Sep; 9(18):R695-7. PubMed ID: 10508600
[TBL] [Abstract][Full Text] [Related]
17. Mechanistic insights into the efficacy of cell penetrating peptide-based cancer vaccines.
Grau M; Walker PR; Derouazi M
Cell Mol Life Sci; 2018 Aug; 75(16):2887-2896. PubMed ID: 29508006
[TBL] [Abstract][Full Text] [Related]
18. New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models.
Lopes A; Bastiancich C; Bausart M; Ligot S; Lambricht L; Vanvarenberg K; Ucakar B; Gallez B; Préat V; Vandermeulen G
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795383
[TBL] [Abstract][Full Text] [Related]
19. The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity.
Wang RF
Trends Immunol; 2001 May; 22(5):269-76. PubMed ID: 11323286
[TBL] [Abstract][Full Text] [Related]
20. [Immunotherapy of solid tumor: perspectives on vaccine and cell therapy].
Ikeda H; Shiku H
Nihon Rinsho; 2012 Dec; 70(12):2043-50. PubMed ID: 23259373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
